|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Pfizer |
| Information provided by: | Pfizer |
| ClinicalTrials.gov Identifier: | NCT00068042 |
Purpose
The purpose of the study is to determine if Pegvisomant is more efficacious than Sandostatin LAR Depot in normalizing IGF-I levels in treatment naive patients with acromegaly.
| Condition | Intervention | Phase |
|
Acromegaly |
Drug: Pegvisomant Drug: Sandostatin LAR |
Phase IV |
| Drug Information available for: | Octreotide Octreotide acetate |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly |
| Estimated Enrollment: | 100 |
| Study Start Date: | April 2003 |
| Study Completion Date: | May 2006 |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations![]() |
Show 55 Study Locations |
| Pfizer |
| Study Director: | Pfizer CT.gov Call Center | Pfizer |
More Information
To obtain contact information for a study center near you, click here. 
  |
Link to ClinicalStudyResults.org Posting: 
  |
| Study ID Numbers: | PEGA-0435-003, A6291004 |
| First Received: | September 4, 2003 |
| Last Updated: | April 3, 2008 |
| ClinicalTrials.gov Identifier: | NCT00068042 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|